Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital and Pointsharp in connection with their strategic acquisition of SecMaker
Mandate

Vinge has advised Main Capital and Pointsharp in connection with their strategic acquisition of SecMaker

July 08, 2021 Employment and Benefits Commercial Agreements M&A Intellectual Property

Pointsharp enables organizations to secure IT environments with a high-level of control for IT departments combined with an intuitive mobile user experience.

Pointsharp has a broad solution offering in the identity and access management market related to multi-factor authentication, secure access, user provisioning and password management. SecMaker is a leading security provider in complex system environments with a strong footprint in the healthcare and government sectors. The combination of Pointsharp and SecMaker creates a leading security software provider in the Swedish market with strong potential for future North-Western European growth.

Vinge’s team consisted of counsel Filip Öhrner and associates Vilhelm Rondahl, Gustav Lindgren (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (GDPR/IT), Rebecka Weitzberg (IP), Lisa Hörnqvist (Agreements) and VDR assistant Carl Bruneheim (VDR).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026